Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide

被引：0

作者：

Orkin, Chloe ^{[1
]}

Antinori, Andrea ^{[2
]}

Rockstroh, Juergen ^{[3
]}

Guillen, Santiago Moreno ^{[4
]}

Martorell, Claudia ^{[5
]}

Molina, Jean-Michel ^{[6
]}

Lazzarin, Adriano ^{[7
]}

Maggiolo, Franco ^{[8
]}

Yazdanpanah, Yazdan ^{[9
]}

Andreatta, Kristen ^{[10
]}

Huang, Hailin ^{[10
]}

Hindman, Jason ^{[10
]}

Martin, Hal ^{[10
]}

Baeten, Jared ^{[10
]}

Pozniak, Anton ^{[11
]}

机构：

[1] Queen Mary Univ London, London, England

[2] Natl Inst Infect Dis, Lazzaro Spallanzani, Rome, Italy

[3] Univ Hosp Bonn, Bonn, Germany

[4] Hosp Ramon & Cajal, Madrid, Spain

[5] Res Inst Springfield, Springfield, MO USA

[6] Univ Paris, Paris, France

[7] San Raffaele Hosp Milan, Milan, Italy

[8] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy

[9] AP HP Hop Bichat, Paris, France

[10] Gilead Sci Inc, Foster City, CA USA

[11] Chelsea & Westminster Hosp, London, England

来源：

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

P002

引用

页码：21 / 22

页数：2